Weight loss injections are inching their way into elementary schools. New data presented at an obesity conference this week show that Novo Nordisk’s Wegovy cut body mass index by an average of 13.5% in kids ages 6 to 11, while a diet-and-exercise-only group saw BMI tick up roughly 3%, reports the Wall Street Journal. However, children on Wegovy grew about 1.3 inches less than peers not taking the drug, raising questions about long-term height and development that researchers say could take years to answer. Eli Lilly’s Zepbound lowered BMI by about 18.5% in adolescents and didn’t appear to slow growth.
Both drugs improved blood sugar and some cholesterol, but they caused nausea and vomiting in many, and up to 17% of trial participants quit. With nearly 1 in 5 US children considered obese, experts are split on whether the benefits justify the unknowns. “The question is: Is this the right thing to do?” says UC San Francisco pediatrics professor Robert Lustig, per the New York Times. “Not: Does it work? Of course it works. But is it the right thing?” The World Health Organization recently issued guidance recommending against using such weight loss meds in kids 9 and under, per Forbes. PolitiFact lays out seven things parents should know before putting their children on GLP-1 meds.